This century-old inn on the Outer Banks is getting another chance. Take a look
Feb. 2 John and Pam Buchholz have traveled the world, welcoming new experiences and embarking on adventures.
But Pam Buchholz, who grew up on the coast of Scotland, says she fell in love with Hatteras Island the first time she visited that stretch of North Carolina s Outer Banks.
So when she stumbled across an online listing for the century-old Atlantic Inn last year, she knew she wanted to buy the suffering hotel and breathe new life into it.
There was a problem, though: Coronavirus-related restrictions prevented her husband from visiting the building. So he agreed to buy it without ever seeing it in person.
This century-old inn on the Outer Banks is getting another chance
Feb. 2 John and Pam Buchholz have traveled the world, welcoming new experiences and embarking on adventures.
But Pam Buchholz, who grew up on the coast of Scotland, says she fell in love with Hatteras Island the first time she visited that stretch of North Carolina s Outer Banks.
So when she stumbled across an online listing for the century-old Atlantic Inn last year, she knew she wanted to buy the suffering hotel and breathe new life into it.
There was a problem, though: Coronavirus-related restrictions prevented her husband from visiting the building. So he agreed to buy it without ever seeing it in person.
Evotec AG: Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation
DEVELOPMENT OF EVT894 BY EVOTEC TOGETHER WITH ITS PARTNERS NIAID AND DUKE CLINICAL RESEARCH INSTITUTE
ADDRESSING UNMET MEDICAL NEEDS IN GLOBAL HEALTH
HAMBURG, GERMANY / ACCESSWIRE / January 28, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development.
The Phase I, randomised, double-blind, single centre, single dose escalation study to evaluate the safety, pharmacokinetics, and immunogenicity of EVT894 vs placebo in healthy volunteers (five dose-cohorts of 8 subjects) is sponsored and funded by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health with funds from a Phase I Clinical Trial Units for Therapeutics programme awar
First-of-its-kind cardiovascular drug gets FDA approval based on study from Canadian VIGOUR Centre
The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study run by researchers at the University of Alberta s Canadian VIGOUR Centre.
As reported in March 2020, vericiguat works by stimulating an enzyme in the body called soluble guanylate cyclase (sGC), which is important for enhancing heart function and helping blood vessels relax to provide better blood flow. In patients with heart failure, sGC is reduced and unable to adequately stimulate cyclic guanosine monophosphate (cGMP), necessary for transmitting chemical signals to blood vessels, which results in vascular and coronary dysfun
E-Mail
The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study run by researchers at the University of Alberta s Canadian VIGOUR Centre.
As reported in March 2020, vericiguat works by stimulating an enzyme in the body called soluble guanylate cyclase (sGC), which is important for enhancing heart function and helping blood vessels relax to provide better blood flow. In patients with heart failure, sGC is reduced and unable to adequately stimulate cyclic guanosine monophosphate (cGMP), necessary for transmitting chemical signals to blood vessels, which results in vascular and coronary dysfunction.